KVUE at a glance
Kenvue (KVUE, SEC CIK 1944048) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), Kenvue (KVUE) reported revenue of $15.1 billion (down 2.1% from FY2024) and net income of $1.5 billion. Diluted EPS was $0.76.
- As of June 30, 2026, 41 institutional investment managers tracked by SignalX reported holding Kenvue (KVUE) shares worth $17.9 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $15.1B
- −2.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 41 funds
- $17.9B · +2 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 28, 2025
Business Overview
- Core business: Global pure-play consumer health company with $15.1B FY2025 sales, focused on Self Care, Skin Health & Beauty, and Essential Health segments
- New emphasis: Completed full independence from J&J by August 2023, exiting TSAs and building standalone systems and capabilities
- Strategic shift: Entered merger agreement with Kimberly-Clark in Nov 2025, aiming to combine consumer health and personal care portfolios
- Quantitative metrics: Approximately 22,000 employees globally as of Dec 2025, with 23% in North America, 28% EMEA, 30% APAC, 19% LATAM
- Noteworthy fact: FY2025 in-house manufacturing covered 60% of sales volume, rest from third-party suppliers, supporting global operational flexibility
Risk Factors
- Regulatory risk from Section 368(a) Internal Revenue Code uncertainty; potential additional U.S. federal income taxes if Proposed Transaction fails to qualify as a “reorganization”
- Geopolitical/macroeconomic risk with inflationary pressures and raw material cost volatility linked to military conflicts and tariffs
- Operational risk from reliance on third-party manufacturing and supply chains causing potential disruptions to operations
- Competitive risk from intense competition across all segments from multinational corporations, smaller regional companies, private-label, and generic products
- Financial risk due to increased Kimberly-Clark indebtedness from Proposed Transaction financing, reducing cash flow available for debt servicing and increasing liquidity risk
Management Discussion & Analysis
- Operating cash flow $2.2B in FY 2025, up $428M from $1.8B in FY 2024, driven by working capital timing in payables and receivables
- Financing cash outflow $1.8B in FY 2025 vs $1.6B in FY 2024; included $1.58B dividends, $197M share repurchases, $750M debt repayment, $746M long-term notes issuance
- Capital expenditures $475M in FY 2025, slight increase from $425M investing outflows in prior year
- Share repurchases totaled $197M for ~9.18M shares before merger agreement restriction; no repurchases post-merger agreement signed Nov 2025
- Management expects sufficient liquidity from $1.1B cash, $2.2B operating cash flow, $4B credit facility, and $4B commercial paper; warns financing availability risk
AI summary of the KVUE 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 28, 2026
Management Discussion & Analysis
- Revenue $3,955M, up $116M or 3.0% YoY; organic sales up 1.6%
- Gross margin 58.2% vs 58.9% YoY; operating income $699M vs $692M
- Best segment Skin Health and Beauty: sales $1,113M, up 5.1%; adjusted operating income $186M, up 24.8%
- Worst segment Essential Health: adjusted operating income $315M, down 10.3% YoY
- Headwinds include approximately $80M annualized gross tariff exposure and continued Middle East supply-chain volatility
Risk Factors
- Pending Kimberly-Clark acquisition restricts equity repurchases without K-C’s prior written consent
- Merger Agreement dated November 2, 2025 creates transaction-execution risk
- Share repurchases halted after merger execution, leaving 6,613 thousand authorized shares
- No new or changed 10-Q risk factors disclosed beyond the Annual Report reference
AI summary of the KVUE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 2026 results for quarter ended June 28, 2026
- Kenvue issued results press release on August 6, 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 12 director nominees elected, preserving board continuity through the 2027 annual meeting
- Director support remained strong, with lowest “For” vote of 1,483,722,493 for Betsy D. Holden
Item 2.02: Results of Operations and Financial Condition
- Fiscal first-quarter results ended March 29, 2026, announced May 7, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1
AI summaries of KVUE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KVUE
Don't miss the next KVUE filing
- Alerts as it files. A push when KVUE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KVUE, by share count.
- Ask anything. An AI agent that reads every KVUE filing and answers with sources.
KVUE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Howlett Heather | F | Oct 2, 2026 | 5,566 | $17.20 |
| Stevens Meredith | A | Oct 2, 2026 | 35,754 | $17.20 |
| Howlett Heather | A | Oct 2, 2026 | 10,881 | $17.20 |
| Stevens Meredith | F | Oct 2, 2026 | 15,192 | $17.20 |
| Orlando Matthew | A | Oct 2, 2026 | 35,754 | $17.20 |
| Orlando Matthew | F | Oct 2, 2026 | 14,749 | $17.20 |
| Tillett Caroline | A | Oct 2, 2026 | 24,732 | $17.20 |
| Tillett Caroline | F | Oct 2, 2026 | 8,471 | $17.20 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $15.5B | $15.1B |
| Gross Profit | - | $9.0B | $8.8B |
| Operating Income | - | $1.8B | $2.4B |
| Net Income | - | $1.0B | $1.5B |
| Gross Margin | - | 58.0% | 58.1% |
| Op. Margin | - | 11.9% | 16.0% |
| Net Margin | - | 6.7% | 9.7% |
| Balance Sheet | |||
| Total Assets | $27.9B | $25.6B | $27.1B |
| Equity | $11.2B | $9.7B | $10.8B |
| ROE | - | 10.7% | 13.7% |
| Per Share | |||
| EPS | - | $0.54 | $0.76 |
| Cash Flow | |||
| Operating CF | - | $1.8B | $2.2B |
| CapEx | - | $434.0M | $475.0M |
Source: XBRL data in Kenvue (KVUE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KVUE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 41 | $17.88B |
| Q1 2026 | 39 | $15.53B |
| Q4 2025 | 38 | $14.80B |
| Q3 2025 | 42 | $16.60B |
| Q2 2025 | 40 | $22.35B |
| Q1 2025 | 36 | $18.45B |
| Q4 2024 | 30 | $14.11B |
| Q3 2024 | 25 | $6.35B |
- FMR LLC (Fidelity)+21.96M (+16%)
- JPMorgan Chase & Co+13.40M (+104%)
- BlackRock+5.53M (+4%)
- Millennium Management+5.14M (+16%)
- Renaissance Technologies LLC+4.88M (+118%)
- D.E. Shaw & Co−18.67M (-71%)
- T. Rowe Price Group−4.79M (-24%)
- Invesco Ltd−2.58M (-14%)
- BNY Mellon−813.3K (-7%)
- AQR Capital Management−611.6K (-27%)
- Two Sigma Investments+187.9K
- WESTWOOD HOLDINGS GROUP INC+34.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 291 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KVUE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 28, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - |
Related Consumer Staples companies
- CL · Colgate-PalmolivePerfumes, Cosmetics & Other Toilet Preparations
- EPC · EDGEWELL PERSONAL CARE CoPerfumes, Cosmetics & Other Toilet Preparations
- EL · Estée Lauder Companies (The)Perfumes, Cosmetics & Other Toilet Preparations
- IPAR · INTERPARFUMS INCPerfumes, Cosmetics & Other Toilet Preparations
- OLPX · OLAPLEX HOLDINGS, INC.Perfumes, Cosmetics & Other Toilet Preparations
- SLSN · SOLESENCE, INC.Perfumes, Cosmetics & Other Toilet Preparations
- WALD · Waldencast plcPerfumes, Cosmetics & Other Toilet Preparations
- ACI · Albertsons Companies IncRetail-Grocery Stores
KVUE SEC filings: frequently asked questions
Which institutions hold KVUE stock?
As of June 30, 2026, the largest Kenvue (KVUE) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($3.0 billion), BlackRock ($2.9 billion), Vanguard Capital Management LLC ($2.4 billion), State Street Corp ($2.3 billion), Vanguard Portfolio Management LLC ($1.8 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KVUE's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), Kenvue (KVUE) reported revenue of $15.1 billion (down 2.1% from FY2024) and net income of $1.5 billion. Diluted EPS was $0.76. The figures come from the XBRL data in the 10-K.
What are the main risks in KVUE's latest 10-K?
In the 10-K filed February 20, 2026, Kenvue (KVUE) flagged: Regulatory risk from Section 368(a) Internal Revenue Code uncertainty; potential additional U.S. federal income taxes if Proposed Transaction fails to qualify as a “reorganization”. Geopolitical/macroeconomic risk with inflationary pressures and raw material cost volatility linked to military conflicts and tariffs. (AI summary of the Risk Factors section.)
What did KVUE report in its latest 8-K?
Kenvue (KVUE) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q2 2026 results for quarter ended June 28, 2026.
What are the latest KVUE SEC filings?
Kenvue (KVUE) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 6, 2026.
What is KVUE's SEC CIK number?
Kenvue (KVUE)'s SEC Central Index Key (CIK) is 1944048. EDGAR lists every KVUE filing under that number.
Ask anything about KVUE
The research agent reads KVUE's filings, financials, insider trades and 13F holders, then answers with sources.